Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 1, 2006, Pages

  Katzenstein, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NEVIRAPINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADD ON THERAPY; AFRICA; CONFERENCE PAPER; EPIDEMIC; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; TREATMENT INDICATION; VIRUS MUTATION; VIRUS RECOMBINATION;

AFRICA; ANTI-HIV AGENTS; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RECOMBINATION, GENETIC; VARIATION (GENETICS);

EID: 33748866494     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505353     Document Type: Conference Paper

References (29)

1. Martin D, Katzenstein DA, Yu G, Jordan MC. CMV viremia detected by nucleic acid hybridization and electron microscopy. Ann Intern Med 1984; 100:222-5.
2. Chou S, Merigan TC. Rapid detection and quantitation of human cytomegalovirus in urine through DNA hybridization. N Engl J Med 1983; 308:921-5.
3. Katzenstein DA, Yu G, Jordan MC. Lethal murine cytomegalovirus infection is mediated by early replication in splenic macrophages. J Infect Dis 1983; 148:406-11.
4. Katzenstein DA, Crane RT, Jordan MC. Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection. J Lab Clin Med 1986; 108:155-60.
5. Katzenstein DA, Latif AS, Grace S, et al. Clinical and laboratory characteristics of human immunodeficiency virus infection in Zimbabwe. J Acquir Immune Defic Syndr 1990; 3:701-7.
6. Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS 1989; 3:519-23.
7. World Health Organization. State of the epidemic 2004, the impact of HIV/AIDS. Geneva: Joint United Nations Programme on HIV/AIDS, World Health Organization, 2002.
8. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J, WHO-UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29:184-90.
9. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes. Nature 1999; 397:436-41.
10. Hahn BH, Shaw GM, De Cock KM, Sharp PM. AIDS as a zoonosis: scientific and public health implications. Science 2000; 287:607-14.
11. Korber B, Muldoon M, Theiler J, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000; 288:1789-96.
12. Roda RH, Balakrishnan M, Hanson MN, et al. Role of the reverse transcriptase, nucleocapsid protein, and template structure in the two-step transfer mechanism in retroviral recombination. J Biol Chem 2003; 278:31536-46.
13. Grobler J, Gray CM, Rademeyer C, et al. Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers. J Infect Dis 2004; 190:1355-9.
14. Hu DJ, Subbarao S, Vanichseni S, et al. Frequency of HIV-1 dual subtype infections, including intersubtype superinfections, among injection drug users in Bangkok, Thailand. AIDS 2005; 19:303-8.
15. Eshleman SH, Gonzales MJ, Becker-Pergola G, et al. Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D. AIDS Res Hum Retroviruses 2002; 18:507-11.
16. Koulinska IN, Msamanga G, Mwakagile D, Essex M, Renjifo B. Common genetic arrangements among human immunodeficiency virus type 1 subtype A and D recombinant genomes vertically transmitted in Tanzania. AIDS Res Hum Retroviruses 2002; 18:947-56.
17. Renjifo B, Gilbert P, Chaplin B, et al. Emerging recombinant human immunodeficiency viruses: uneven representation of the envelope V3 region. AIDS 1999; 13:1613-21.
18. Rose PP, Korber BT. Detecting hypermutations in viral sequences with an emphasis on G→A hypermutation. Bioinformatics 2000; 16:400-1.
19. Walker PR, Pybus OG, Rambaut A, Holmes EC. Comparative population dynamics of HIV-1 subtypes B and C: subtype-specific differences in patterns of epidemic growth. Infect Genet Evol 2005; 5:199-208.
20. Montano MA, Nixon CP, Ndung'u T, et al. Elevated tumor necrosis factor-α activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-κB enhancer gain-of-function. J Infect Dis 2000; 181:76-81.
21. Montano MA, Novitsky VA, Blackard JT, Cho NL, Katzenstein DA, Essex M. Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol 1997; 71:8657-65.
22. van Opijnen T, Jeeninga RE, Boerlijst MC, et al. Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner. J Virol 2004; 78:3675-83.
23. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-73.
24. Ping LH, Cohen MS, Hoffman I, et al. Effects of genital tract inflammation on human immunodeficiency virus type 1 V3 populations in blood and semen. J Virol 2000; 74:8946-52.
25. Shafer RW, Eisen J, Merigan TC, Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol 1997; 71:5441-8.
26. Shafer RW, Chaung T, Hsu P, White CB, Katzenstein DA. Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses 1999; 15:65-9.
27. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
28. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 2005; 192: 30-6.
29. Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2005; 2:e112.